Introduction {#section5-1178223419828766}
============

Breast cancer (BC) is usually detected in postmenopausal women. Although the average age of BC onset is at 61 years, about 1 in 40 women diagnosed with the disease are very young, and this subset has a higher mortality rate, with 5% to 7% of all deaths from BC belonging to this group.^[@bibr1-1178223419828766],[@bibr2-1178223419828766]^

There are numerous risk factors associated with BC, most of them related to women's reproductive histories and their lifetime hormonal exposure. These factors include age, age at menarche (the onset of menarche aged less than 11 years),^[@bibr3-1178223419828766][@bibr4-1178223419828766]-[@bibr5-1178223419828766]^ age at menopause, and age of first pregnancy.^[@bibr6-1178223419828766][@bibr7-1178223419828766]-[@bibr8-1178223419828766]^ Protective factors include prolonged breastfeeding status^[@bibr7-1178223419828766],[@bibr9-1178223419828766]-[@bibr10-1178223419828766]^ and moderated alcohol consumption.^[@bibr11-1178223419828766][@bibr12-1178223419828766][@bibr13-1178223419828766]-[@bibr14-1178223419828766]^ In addition, body mass index (BMI) has been considered as a risk factor in older BC patients but protective in young women.^[@bibr14-1178223419828766]^ Finally, women with a family history of BC and/or *BRCA* mutations have an increased risk of BC.^[@bibr15-1178223419828766][@bibr16-1178223419828766]-[@bibr17-1178223419828766]^

The definition of "youth" in BC is controversial, with the age threshold ranging between 30 and 45 years. However, recent studies show that in patients younger than 35 years, the risk of death from BC increased by about 5% per year. Thus, 35 years appears to be the most reasonable cut-off age for clinically defining BC in very young women (BCVY).^[@bibr18-1178223419828766],[@bibr19-1178223419828766]^

The reason for increased mortality in BCVY patients is that their tumors often exhibit more aggressive pathological features. These include larger tumor size, higher histological grades, a higher percentage of lymph node invasion, human epidermal growth factor receptor 2 (HER2) overexpression, and triple negative tumors than their older counterparts.^[@bibr20-1178223419828766][@bibr21-1178223419828766][@bibr22-1178223419828766][@bibr23-1178223419828766][@bibr24-1178223419828766][@bibr25-1178223419828766][@bibr26-1178223419828766][@bibr27-1178223419828766][@bibr28-1178223419828766]-[@bibr29-1178223419828766]^

We performed an exhaustive clinicopathological study on a cohort of 258 Spanish BCVY patients, with the aim of identifying whether BCVY patients exhibit different clinical and/or socio-cultural background characteristics compared with older patients and whether they are likely to have a molecular basis.

Methods {#section6-1178223419828766}
=======

Patient selection {#section7-1178223419828766}
-----------------

All the subjects were selected from a database of 6072 BC patients diagnosed between 1998 and 2014 at the Hematology and Medical Oncology Unit in the Hospital Clínico Universitario de Valencia, Spain. We identified 258 young (⩽35 years) BCVY women. We used a random selected group of 101 postmenopausal women from the entire group of older patients diagnosed with BC to not bias the comparisons; they were aged between 45 and 95 years as had been used as a control group. The study was approved by the Ethics Board at our hospital and all the subjects gave their written informed consent for their inclusion.

All the patients' clinical data were collected at their first visit, and information about their pathological characteristics and treatment history was obtained after surgery and following subsequent visits. Tumor size and lymph node involvement were assessed using the seventh edition of the American Joint Committee on Cancer staging manual.^[@bibr30-1178223419828766]^ The patient clinicopathological data used in this study are shown in [Table 1](#table1-1178223419828766){ref-type="table"}. Patients were also classified both according to the type of surgery they underwent and the type of the neoadjuvant/adjuvant treatment they received ([Table 2](#table2-1178223419828766){ref-type="table"}).

###### 

The patient clinicopathological data.

![](10.1177_1178223419828766-table1)

                            BCVY                                                         Old BC   *P* value          
  ------------------------- ------------------------------------------------------------ -------- ----------- ------ ---------------
  Age BCVY/old BC                                                                                                    
  \<25 years/46-50 years    12                                                           4.7      6           5.9    
  25-30 years/50-56 years   60                                                           23.2     55          54.4   
  30-35 years/\>65 years    186                                                          72.1     40          39.6   
  Year of diagnosis                                                                                                  
  Before 2000               60                                                           23       50          49.5   .642
  After 2000                198                                                          77       51          50.5   
  Tumor size                                                                                                         
  \<2 cm                    94                                                           36.4     67          66.3   3.01 × 10^−3^
  2-5 cm                    112                                                          43.4     29          28.7   
  \>5 cm                    35                                                           13.6     5           5      
  Missing                   17                                                           6.6      0           0      
  Lymph node status                                                                                                  
  Node positive             121                                                          46.9     38          37.6   .099
  Node negative             120                                                          46.5     59          58.4   
  Missing                   17                                                           6.5      4           4      
  Grade                                                                                                              
  I                         28                                                           11       18          17.8   .583
  II                        71                                                           27.5     39          38.6   
  III                       94                                                           36.4     39          38.6   
  Missing                   65                                                           25.2     5           5      
  Histologic subtype                                                                                                 
  Ductal                    209                                                          81       73          72.3   .081
  Lobular                   10                                                           4        7           6.9    
  Medullary                 8                                                            3        0           0      
  Tubular                   6                                                            2        4           4      
  Others                    25                                                           10       17          16.8   
  Estrogen receptor                                                                                                  
  Positive                  180                                                          70       72          71.3   .496
  Negative                  62                                                           24       29          28.7   
  Missing                   16                                                           6        0           0      
  Progesterone receptor                                                                                              
  Positive                  153                                                          59.3     69          68.3   .319
  Negative                  87                                                           33.7     32          31.7   
  Missing                   18                                                           7        0           0      
  Ki 67 (%)                                                                                                          
  Low \<14                  20                                                           7.7      18          17.8   .202
  14-30                     46                                                           17.8     32          31.6   
  High \>30                 41                                                           15.8     16          15.8   
  Missing                   151^[a](#table-fn3-1178223419828766){ref-type="table-fn"}^   58.5     35          34.6   
  Her2                                                                                                               
  Positive                  73                                                           28.3     23          22.8   .112
  Negative                  138                                                          53.5     71          70.3   
  Missing                   47^[b](#table-fn4-1178223419828766){ref-type="table-fn"}^    18.2     7           6.9    
  Subtypes                                                                                                           
  Luminal                   131                                                          50.7     62          61.4   .651
  Luminal-Her2              46                                                           17.8     17          16.8   
  Her2 positive             26                                                           10       5           5      
  Triple negative           35                                                           13.5     17          16.8   
  Missing                   20                                                           7.5      0           0      

Abbreviations: BC, breast cancer; BCVY, breast cancer in very young women.

Total number of patients: 258 BCVY and 101 old BC.

The data of Ki 67 were started to be used routinely in the year 2008. Previously lacking these data.

The data of HER2 overexpression are missing because the diagnosis is prior to the knowledge of the role of HER2 in breast cancer.

*P* values were obtained after a Pearson's chi-squared test by R/Bioconductor.

###### 

Type of surgery, neoadjuvant/adjuvant treatment, and relapse.

![](10.1177_1178223419828766-table2)

                                                  BCVY   Old BC   *P* value          
  ----------------------------------------------- ------ -------- ----------- ------ ----------------
  Surgery                                                                            
  Radical mastectomy + lymphadenectomy            98     38       30          29.7   4.7 × 10^−03^
  Radical mastectomy + sentinel node              87     33.7     34          33.6   
  Tumorectomy + sentinel node                     29     11.2     28          27.7   
  Missing                                         44     17       9           8.9    
  Treatment                                                                          
  Chemotherapy                                    218    84.5     73          72.3   3.82 × 10^−09^
  Endocrine therapy only                          10     3.9      24          23.8   
  No treatment                                    0      0        4           3.9    
  Missing                                         30     11.6     0           0      
  Neoadjuvant treatment                                                              
  Yes                                             87     33.7     17          16.8   3.4 × 10^−03^
  No                                              168    65.1     84          83.1   
  Missing                                         3      1.1      0           0      
  Complete response after neoadjuvant treatment                                      
  Yes                                             9      3.5      7           6.9    .460
  No                                              239    92.6     94          93.1   
  Missing                                         10     3.9      0           0      
  Type treatment chemotherapy                                                        
  CMF                                             2      0.8      0           0      1.08 × 10^−05^
  Schema with antracyclines (AC, FEC, FAC)        76     29.5     17          16.8   
  Taxanes                                         28     10.8     21          20.8   
  Clinical trial                                  74     28.7     23          22.8   
  Other                                           20     7.7      12          11.9   
  No treatment with chemotherapy                  20     7.7      28          27.6   
  Missing                                         38     14.7     0           0      
  Relapse                                                                            
  Yes                                             91     35.3     25          24.7   3.5 × 10^−03^
  No                                              105    40.7     76          75.2   
  Missing                                         62     24       0           0      
  Data of relapse                                                                    
  \<1 year                                        24     26.4     7           28     .296
  1-5 years                                       47     51.7     9           36     
  \>5 years                                       20     21.9     9           36     
  Missing                                         0      0        0           0      
  Site of relapse                                                                    
  Locoregional                                    28     30.8     9           36     .849
  Bone                                            19     20.9     3           12     
  Brain                                           1      1.1      1           4      
  Visceral                                        37     40.7     10          40     
  Other                                           6      6.6      2           8      
  Missing                                         0      0        0           0      
  Exitus after relapse                                                               
  Yes                                             38     41.8     8           32     .105
  No                                              26     28.6     14          56     
  Missing                                         27     29.6     3           12     

Abbreviations: AC: 5-Fluoracil, ciclofosfamide; BC, breast cancer; BCVY, breast cancer in very young women; FAC: 5-Fluoracil, 5-Fluoracil and ciclofosfamide; FEC: 5-Fluoracil, Epirrubicin and Ciclofosfamide.

Total number of patients: 258 BCVY and 101 old BC. The missing patients are those who were sent to their referral centers after treatment and missed follow-up. *P* values were obtained after a Pearson's chi-squared test by R/Bioconductor.

Risk factors for BC {#section8-1178223419828766}
-------------------

We studied the age at menarche, age at first pregnancy, lifetime time spent breastfeeding, BMI, family heredity, and the presence of mutations in the *BRCA1* and *BRCA2* genes in both populations ([Table 3](#table3-1178223419828766){ref-type="table"}). Data began to be collected after finding an increase in the incidence of breast cancer in young women in Spain with the suspicion that the change in reproductive habits was the cause.^[@bibr31-1178223419828766],[@bibr32-1178223419828766]^ The criteria for the genetic study of *BRCA1*/*2* genes are defined in [Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1178223419828766).

###### 

The patient reproductive data.

![](10.1177_1178223419828766-table3)

                                   BCVY   Old BC   *P* value           
  -------------------------------- ------ -------- ----------- ------- ----------------
  Menarche                                                             
  ⩽11 years                        48     18.6     14          13.9    .531
  12-14 years                      131    50.7     48          47.5    
  ⩾15 years                        7      2.7      7           6.9     
  Missing                          72     27.9     32          31.7    
  Body mass index                                                      
  \<25                             86     33.3     9           8.9     .078
  25-30                            27     10.4     9           8.9     
  \>30                             3      1.2      1           1       
  Missing                          142    55       82          81.2    
  Pregnancy                                                            
  Yes                              108    41.9     63          62.4    2.74 × 10^−07^
  No                               91     35.3     6           5.9     
  Missing                          59     22.8     32          31.7    
  Age first pregnancy                                                  
  \<20 years                       7      2.7      6           5.9     1.88 × 10^−05^
  20-30 years                      54     20.9     50          49.5    
  \>30 years                       33     12.8     7           6.9     
  Missing                          164    63.5     38          37.6    
  Lactation                                                            
  Yes                              59     22.9     31          30.7    7.6 × 10^−3^
  No                               23     8.9      32          31.7    
  Missing                          176    68.2     38          37.6    
  *BRCA* mutation                                                      
  Yes                              31     12.1     0           0       1.76 × 10^−06^
  No                               58     22.5     8           7.92    
  Do not meet the study criteria   169    65.5     93          92.07   
  Family heredity                                                      
  First grade                      22     8.5      4           4       0.301
  Second grade                     33     12.8     7           6.9     
  First and second grade           15     5.8      3           3       
  Any heredity                     142    55       87          86.1    
  Missing                          46     17.8     0           0       

Abbreviations: BC, breast cancer; BCVY, breast cancer in very young women.

Total number of patients: 258 BCVY and 101 old BC. *P* values were obtained after a Pearson's chi-squared test by R/Bioconductor.

Data collection {#section9-1178223419828766}
---------------

All the tissue samples used were collected after BC surgery or after core needle biopsy (CNB) diagnosis. The formalin-fixed paraffin-embedded tissues were evaluated for their tumor content and sections containing more than 30% tumor cells were defined and cut by a pathologist.

Immunochemistry classification to get the molecular subtypes {#section10-1178223419828766}
------------------------------------------------------------

Four-micrometer-thick sections were deparaffinized in xylene and rehydrated. Antigen retrieval was done by microwaving in 10 mM citric acid monohydrate for 1 × 5 min at 900 W and for 3 × 5 min at 600 W. Endogenous peroxidase activity was blocked by treatment with 0.5% H~2~O~2~. The slides were incubated overnight in a refrigerator at +4°C with appropriate dilutions of the primary antibodies. The reaction was visualized by the Elite ABC Kit (Vectastain, Vector Laboratories, Burlingame, CA, USA) for oestrogen receptor (ER) and by the Envision kit (Dako, Copenhagen, Denmark) for HER2. For progesteron receptor (PR), the sections were subjected to dual colorimetric immunohistochemical (IHC; Envision G/2 Doublestain; Dako).

The result was quantified as the proportion of positively stained tumor cells (range 0%-100%). For the analyses, the tissue samples were classified as positive for ER and PR when ⩾1% of the tumor cells showed positive nuclear staining. In PR dual staining, tumors with ⩾1% Diaminobenzidine (DAB)-stained nuclei or ⩾1% Perm Red-stained cytoplasm were considered positive.

HER2 was scored based on the intensity and percentage of positive cells on a scale of 0 to 3+. Cases were reported 0 (negative) if no staining or membrane staining in less than 10% of invasive tumor cells was seen; 1+ (negative) if faint/barely perceptive membrane staining was detected in more than 10% of invasive tumor cells; 2+ (positive) if weak to moderate complete membrane staining in more than 10% tumor cells or \<30% with strong complete membrane staining; or 3+ (positive) if strong complete membrane staining in more than 30% invasive tumor cells was seen. Regarding evaluation of Ki67, the tumor was considered negative when less than 14% of the tumor cells showed positive stained nuclei, othervwise was positive. However, when staining was between 14 to 30% was considered intermediate expression and positive when staining was higher than 30%. We evaluated the entire tumor area from one representative section of the primary tumor.

Based on the expression of IHC markers for HER2, ER, PR, and Ki67, tumors were classified as triple negative (TNBC) (ER^−^/PR^−^/HER2^−^), HER2^+^, luminal A (ER^+^/PR^+^/HER2^−^/Ki-67 \< 14%), or luminal B (ER^+^/PR^+^/HER2^−^; ER^+^/PR^+^/HER2^−^/Ki-67 ⩾ 14%), following the St. Gallen International Expert Consensus criteria from 2011.^[@bibr33-1178223419828766]^

BRCA1/2 testing {#section11-1178223419828766}
---------------

BC samples from Medical Oncology Unit from "Hospital Universitario Clinico" Valencia that fulfill criteria for BRCA1/2 testing are sent to the Genotyping and Genetic Diagnostic Unit at Central Medical Research Laboratories---University of Valencia to be analyzed. An ethylenediaminetetraacetic acid (EDTA) tube with 8 mL of blood from the patients who complied with the criteria to be screened for BRCA1/2 were sent to the molecular laboratory and after genomic DNA extraction, the samples were sequenced according to manufacturer's protocol in a specific panel to identify alterations using next generation sequencing technology (Illumina-MiSeq).

microRNA analysis {#section12-1178223419828766}
-----------------

We utilized microRNA (miR) expression data from a previous study 19 in which the GeneChip miRNA2.0 microarray (Affymetrix (California, USA) was the tool used. raw data are available on GEO database under access number GSE48088.

Statistical analyses {#section13-1178223419828766}
--------------------

We compared all the different characteristics recorded among BCVY and BC using SPSS, v22.0 (SPSS, Chicago, IL, USA) and Pearson's chi-squared test using R/Bioconductor. Two-sided *P* values were calculated using a *t* test or analysis of variance (ANOVA) depending on the number of groups, and an alpha threshold of 0.05 was set for statistical significance.

Survival analysis was performed using GraphPad Prism v6.0 (GraphPad Software Inc., CA, USA). Progression-free survival (PFS) was defined as the time interval between surgery and the first documented distant relapse. Local recurrence-free survival (LRFS) was defined as the time interval between surgery and the first documented local recurrence. Overall survival (OS) was defined as the time between surgery and death or the last follow-up, whichever occurred first. Kaplan-Meier survival curves were calculated for selected risk factors and the Mantel-Cox test was used to evaluate any differences in OS between groups. We study survival analysis of miRNA expression in patients with axillary lymph node involvement.

Results {#section14-1178223419828766}
=======

Clinicopathological risk factors and patient age {#section15-1178223419828766}
------------------------------------------------

All the clinicopathological data recorded from our sample set are presented in [Table 1](#table1-1178223419828766){ref-type="table"}. From the 11 endpoints investigated, Ki67 staining was not properly recorded in the clinical histories. Ki67 was started to be used routinely in the year 2008; thus, we only had access to Ki67 information in 107 BCVY patients (41.5%) and 66 older patients (65%) and so, results have been calculated with these numbers.

In addition, the results showed that all of the patients included in this study had elevated ER and PR expression levels (70% and 59% in BCVY and 71% and 68% in older, respectively). Even though the data are incomplete for 18% of the BCVY group, HER2 protein overexpression still significantly differed between the groups (28% vs 23% in the BCVY and control groups, respectively). In addition, the lowest proliferation rates (\<14 Ki67 expression) were more commonly found in tumors from older patients rather than in BCVY ([Table 1](#table1-1178223419828766){ref-type="table"}).

Our results indicate that BCVY patients exhibit larger tumors in BCVY. If we consider size as a continuous variable, we have a median tumor size of 3.04 cm vs 2.44 cm in BCVY and control group, respectively (*P* = 7.8 × 10^−3^). In case of categorizing tumors as less than 2 cm, 2-5 cm, and larger than 5 cm, younger patients have an increase in both categories with large tumors (*P* = 3.01 × 10^−3^). Although we observed a trend in presenting an increase of positive nodes in BCVY, this did not reach statistical significance (*P* = .09). Moreover, these large tumors in BCVY appeared with less cell differentiation and greater axillary lymph node involvement than older BC patients do, although analysis did not reach statistical significance. No other significant differences were detected in the two age subgroups ([Table 1](#table1-1178223419828766){ref-type="table"}).

Treatments and patient age {#section16-1178223419828766}
--------------------------

We could get follow-up data from the entire control sample set (101 patients) and from 192 of the young women with infiltrating BC (74%). Data related to type of surgery, type of treatment relapse, and exitus are presented in [Table 2](#table2-1178223419828766){ref-type="table"}. We observed an increase in radical mastectomy and lymphadenectomy (*P* = 4.7 × 10^−3^), chemotherapy (*P* = 3.8 × 10^−9^), and neoadjuvant treatment (*P* = 3.4 × 10^−03^) in BCVY than old BC patients (data presented in [Table 2](#table2-1178223419828766){ref-type="table"}).

Although we did not detect any statistically significant differences in terms of locoregional breast and armpit surgical treatment between the BCVY and older BC patients, we found statistically significant improvements in terms of the surgery itself, with BCVY patients having received more sentinel node biopsy in recent years, since 2000 (*P* \< .005). When taking the type of chemotherapeutic agent used into account, we detect differences among treatments received between patients younger than 35 years and those older than 45 years, such differences reflect that older patients receive less aggressive treatments with lower comorbidities (greater use of endocrine therapy alone, *P* = 3.8 × 10^−09^; no requirement of chemotherapy, *P* = 1.08 × 10^−05^) ([Table 2](#table2-1178223419828766){ref-type="table"}).

We observed an increase in neoadjuvant treatment received by the BCVY patients respect to the older group (*P* = 3.4 × 10^−03^). We further investigate whether these differences were due to a change in clinical practice; therefore, of the 60 BCVY patients diagnosed prior to the year 2000, only seven received neoadjuvant treatment; therefore, we studied whether there was an increase in the number of patients receiving neoadjuvant treatment in recent years. Of those diagnosed between 2001 and 2007, 24 patients from 96 (25%) were treated with chemotherapy before surgery, while more than half of the patients diagnosed from 2008 to 2014 received neoadjuvant treatment (*P* \< 1 × 10^−3^). The pattern was similar in older BC patients: 4% of those diagnosed before 2007 received treatment before surgery, but this rose to 29% for those diagnosed between 2008 and 2014 (*P* = .004). Moreover, there was a higher percentage of complete pathological response (CPR) after neoadjuvant therapy in patients aged more than 45 years than in younger patients, and the highest CPR rate was for pure HER2^+^ tumors in both groups.

Relapse and exitus and patient age {#section17-1178223419828766}
----------------------------------

We studied the association between lymph node status, IHC subtype, axillary lymph node involvement, and relapse in BCVY patients. Our results demonstrate an increase percentage of relapse in BCVY patients compared with the control group (46.4% vs 24.7%, *P* = 3.5 × 10^−03^) ([Table 2](#table2-1178223419828766){ref-type="table"}). When we take into account relapse with affected lymph nodes according to immunohistological categories, we see almost half of young patients with luminal tumors (47.3%), 77.3% of luminal/HER2^+^ tumors, 68% of HER2^+^, and 40% of TNBC had relapsed (*P* = .03) ([Figure 1](#fig1-1178223419828766){ref-type="fig"}). In general, we observed that more than half (56.3%) of BCVY patients relapsed when axillary lymph node involvement was present (*P* = .02).

![Percentage of relapses in BCVY according to breast cancer subtype. Light and dark gray bars represent without and without lymph node involvement, respectively. BCVY indicates breast cancer in very young women.](10.1177_1178223419828766-fig1){#fig1-1178223419828766}

Nearly all imnunochemistry subtypes of BCVY patients (lumnial, Her2 enriched and TNBC) experienced a major relapse compared to control group (old BC) [Figure 2A](#fig2-1178223419828766){ref-type="fig"}, even though they had smaller tumor sizes which have a priori better prognosis ([Figure 2B](#fig2-1178223419828766){ref-type="fig"}). Slightly more BCVY patient relapses ended up in death from the disease compared with control patients (42% vs 32%; *P* \< 1 × 10^−03^). Moreover, we see an increase percentage of death in the more favorable luminal subtypes ([Figure 2C](#fig2-1178223419828766){ref-type="fig"}). Neither group showed any differences in histological prognostic factors when we took the relapse risk, ie, tumor size, histological grade, and proliferation into account.

![Percentage relapse: according to immunohistochemistry subtypes (A), relapse according to initial tumor size (B), exitus according to immunohistochemistry subtypes (C), and exitus according to period of relapse (D) in BCVY (pale gray) and old BC (dark gray).](10.1177_1178223419828766-fig2){#fig2-1178223419828766}

Furthermore, our results showed an inverse association between the time from diagnosing the first relapse and the probability of dying from the disease in BCVY patients. The shorter the time, the higher the likelihood that the patient would die from the disease, so that 58% of BCVY patients who relapsed within 1 year died from the disease. This risk reduced to 38% when the relapse was diagnosed at 1-5 years and to 19% when the patient relapsed more than 5 years later (*P* = 2.00 × 10^−3^; [Figure 2D](#fig2-1178223419828766){ref-type="fig"}). Importantly, this trend was not observed in older BC patients. Moreover, we also found an association between risk of death from BC and the location of the first relapse in BCVY patients: patients with a local relapse had a greater chance of survival, but presentation of a visceral or BCVY patients relapsed in major proportion at distant sites, which results in an increased risk and worse prognosis. We see in BCVY patients, 63 with a distant relapse, 13 with local relapse, and 15 with contralateral relapse. In comparison, only 12 old BC had relapse at a distant site (48%), 11 ipsilateral (44%), and finally 2 with contralateral relapse (8%).

Reproductive data and patient age {#section18-1178223419828766}
---------------------------------

Finally, the patient's reproductive data are presented in [Table 3](#table3-1178223419828766){ref-type="table"}. From all the factors described, we encounter high missing data on age at first pregnancy and lactation (63.5% and 68% in BCVY, respectively). Weight is not routinely recorded in the clinical data, therefore, BMI data is composed by only 116 BCVY patients (45%) being highly absent in older patients also. Our results shown that 74% of BCVY patients have normal BMI. Data in older patients are not conclusive.

Although we have information regarding age at menarche only in 86 BCVY patients, we saw that over the last 15 years, the number of BCVY patients with menarche at younger than 11 years has increased (by an average of 8% in the last 7 years with respect to the year 2000). Before the year 2000, at least 68% of BCVY patients carried at least one pregnancy to term; however, in the last 14 years, that number decreased by an average of 16%. In addition, more cases of BCVY were diagnosed during pregnancy, representing a 6% of BCVY cases in the last 6 years compared with 1.7% before the year 2000. The prevalence of BCVY diagnoses in breastfeeding women is also increasing, from 1% before 2000 to a 4% over the last 6 years ([Table 3](#table3-1178223419828766){ref-type="table"}).

Regarding *BRCA1*/*2* mutations, only 31 of the 89 BCVY patients tested (34.8%) were positive. The rest of BCVY patients (169) either did not meet criteria, because they were older than 30 years, or the study was carried out in another center and data are not available. Another eight older patients who met the criteria were also studied but no alterations were found. From the 31 BCVY patients with one *BRCA1*/*2* mutation, 7 (24.4%) presented luminal A/B tumors, 4 (22.2%) were HER2^+^, 4 (21.4%) were luminal/HER2, and 16 (53.3%) were triple negative (*P* = .147).

Differential gene expression in tumors from very young or older women based on their miRNA expression profiles {#section19-1178223419828766}
--------------------------------------------------------------------------------------------------------------

We identified a unique profile of deregulated microRNAs (miR-30c, miR-125a, miR-17, miR-92b, miR-139, and miR-663) associated with BCVY patients.^[@bibr19-1178223419828766]^ Here we investigated any potential links between this differential molecular signature and clinicopathological risk factors in these patients. BCVY patients with axillary lymph node involvement had a significantly higher risk of BC relapse. Thus, we assessed whether any of the aforementioned BCVY- miRs signature was also associated with more aggressive axillary lymph node metastases in BCVY. However, due to the limited patient sample size in this study, we were only able to perform survival analysis in 11 BCVY and 2 control group patients with axillary lymph node involvement.

Although we observed no significant differences for any of these miRNAs (probably because of the small sub-sample cohort), we were able to differentiate between the two groups based on hsa-miR-30c expression with a trend to significance (*P* = .080). Patients with axillary involvement and reduced miR-30c expression levels had a lower OS than those with normal or increased miR-30c expression. The difference was more evident in BCVY patients: seven of them showed a repressed miR-30c status, four of whom died, while control group patients exhibiting miR-30c repression are still alive and have not suffered any relapses ([Figure 3](#fig3-1178223419828766){ref-type="fig"}).

![Kaplan-Meier curve for overall survival in those BCVY (A) and BC (B) patients who had nodal involvement according to miR-30-c expression deregulation. Overexpression of miRNA is shown in light gray and repression in black. BC indicates breast cancer; BCVY, breast cancer in very young women.](10.1177_1178223419828766-fig3){#fig3-1178223419828766}

Discussion {#section20-1178223419828766}
==========

BC is the leading cause of cancer death in young women in developed countries; moreover, younger age at diagnosis usually correlates with more aggressive biological tumor characteristics. Based on previously published information,^[@bibr18-1178223419828766]^ we took 35 years as the threshold age for consideration as part of our young patient cohort, which included 258 BCVY patients, representing one of the largest populations of BCVY patients so far studied.

Pathological and clinical differences between BC in younger and older women and survival analysis by subgroup {#section21-1178223419828766}
-------------------------------------------------------------------------------------------------------------

Over the last 20 years, multiple prospective and retrospective studies have proven that BCVY (⩽35 years) has a worse prognosis than a BC diagnosis in older women,^[@bibr18-1178223419828766][@bibr19-1178223419828766]-[@bibr20-1178223419828766],[@bibr22-1178223419828766][@bibr23-1178223419828766][@bibr24-1178223419828766][@bibr25-1178223419828766]-[@bibr26-1178223419828766]^ Consistent with most previous findings for similar patient cohorts,^[@bibr34-1178223419828766][@bibr35-1178223419828766][@bibr36-1178223419828766][@bibr37-1178223419828766][@bibr38-1178223419828766][@bibr39-1178223419828766]-[@bibr40-1178223419828766]^ our data indicate that BCVY patients tend to present larger, less differentiated BCVY tumors with a higher percentage of axillary lymph node involvement than older BC patients do.

When we look at the molecular prognostic factors, our data show that tumors both in young and older women express a higher percentage of ER than the proportion described in other series such as that by Karihtala and collaborators.^[@bibr1-1178223419828766]^ Moreover, our data demonstrate that a higher percentage of BCVY patient's present HER2^+^ tumors compared with their older counterpart controls, whereas published data regarding this latter prognostic factor differ. Some studies found no differences^[@bibr1-1178223419828766],[@bibr34-1178223419828766]^ while others observed increased HER2 amplification.^[@bibr28-1178223419828766],[@bibr41-1178223419828766][@bibr42-1178223419828766][@bibr43-1178223419828766][@bibr44-1178223419828766]-[@bibr45-1178223419828766]^

Regarding locoregional breast and armpit treatment, we would like to highlight the fact that the type of breast and sentinel armpit surgery performed on young women over the last two decades tended to be more conservative (*P* \< .005). This practice matches the recent tendency of performing the least aggressive surgery possible to achieve lower patient morbidity.^[@bibr46-1178223419828766][@bibr47-1178223419828766][@bibr48-1178223419828766]-[@bibr49-1178223419828766]^ On the other hand, in agreement with previously published studies,^[@bibr50-1178223419828766][@bibr51-1178223419828766]-[@bibr52-1178223419828766]^ we also observed the increased implementation of neoadjuvant chemotherapy treatments, which reached significance for BCVY patients.

We found that only 8% of older patients meet criteria for BRCA testing against 35% of young women. Also, in concordance with published literature,^[@bibr31-1178223419828766],[@bibr53-1178223419828766]^ we found that BRCA gene mutations are far more common in young women. Our results also show an even distribution across the molecular cancer subtypes in all the BCVY patients with a *BRCA* mutation. However, those with triple negative BC subtype showed a higher percentage of *BRCA1/2* mutations consistent with data published in 2012 by Criscitiello and colleagues.^[@bibr54-1178223419828766]^

Regarding disease relapse and OS in our studied patients, nearly half of the BCVY women were diagnosed with a BC relapse compared with just a quarter of older women. No IHC subtype seems to be associated with an increased risk of relapse, neither in youngsters nor in older ones, given that the differences are not statistically significant. Nevertheless, it does seem that axillary involvement has a statistically significant relationship with the risk of relapse in young women, and the significance remains if, in addition to axillary involvement, we associate the luminal/HER2 subtype. The axillary involvement thus could be considered as an independent histological prognostic factor.

However, our comparisons of all these clinicopathological factors did not highlight any associations between the tumor subtypes and increased risk of relapse, in either group. Furthermore, there was a statistically significant relationship between axillary lymph node involvement and the risk of relapse in BCVY women. Moreover, our study confirms that axillary lymph node involvement after surgery is the only independent histological prognostic factor in BCVY patients and confirms the results in Asian populations, published by Zhao and colleagues in 2015.^[@bibr55-1178223419828766]^

Regarding death from BC, we concluded that the risk of dying from this disease is significantly associated with the presentation and characteristics of a first relapse, both in our young and older patients. Moreover, if this relapse appears before the year of diagnosis or is in the form of visceral or cerebral relapse, it is associated, in a statistically significant way, with exitus in young women. For this reason, a more thorough follow-up should be considered in young patients, especially in the first year after diagnosis. Furthermore, in agreement with the literature,^[@bibr43-1178223419828766]^ relapse is much more strongly associated with a prognosis of death in BCVY patients when it occurs within the first year after the initial BC diagnosis, or when the relapse presents in visceral or brain tissue.

Reproductive differences between BC in young and older women {#section22-1178223419828766}
------------------------------------------------------------

We also analyzed whether there were any differences in reproductive factors between our two groups, according to the indications set out in the GRELL study in European women^[@bibr56-1178223419828766]^ and by Pollan and colleagues^[@bibr57-1178223419828766]^ in a Spanish population. Most of our cases were BCVY women diagnosed in recent years (77% of them after the year 2000). Our results reflect the tendency observed in reproductive factors of the Spanish female population over the last 20 years, characterized by a decline in fertility and age at menarche, accompanied by an increase in age at first pregnancy.

Similar to the aforementioned studies, our findings showed an increased BCVY incidence correlated with younger age (\<11 years) at menarche. Moreover, 68% of old women (control group) had had at least one pregnancy compared with patients 16% in BCVY. We also detected an increase in the number of young patients diagnosed with BC during pregnancy over the last 10 years (1.7% of diagnoses between 1998 and the year 2000 to vs 6% over the last 6 years). In addition, we observed a similar increase in the diagnosis of BC in breastfeeding women, rising from 1% from 1998 to 2008 to 4% over the last 6 years.

Genetic differences between BC in young and older women {#section23-1178223419828766}
-------------------------------------------------------

Current studies concerning why young women develop more aggressive BC than older patients are insufficient, mildly suggesting that increased tumor aggressiveness is likely due to biological differences. In our previously published work, we identified a signature of differential expression of microRNAs in BCVY patients.^[@bibr19-1178223419828766]^ Here, we checked an association between this signature and axillary lymph node involvement, and the risk of relapse. We decided to study the correlation between miRNAs and axillary lymph node involvement since in the clinical data presented above there was a significant correlation between lymph node involvement and risk of relapse due to the disease. However, our limited sample of BCVY patients with axillary lymph node involvement prevented us from demonstrating any associations with confidence. Nonetheless, it appears that patients in this subgroup with decreased miR-30c expression did have a higher risk of dying from their disease. This is consistent with other descriptions in the scientific literature, where miR-30c is identified as a prognosis biomarker in BC, has been shown to be involved in chemotherapy resistance and cell invasion, and is associated with the epidermal growth factor receptor (EGFR) and erbB4 signaling pathways.^[@bibr58-1178223419828766][@bibr59-1178223419828766]-[@bibr60-1178223419828766]^

Conclusions {#section24-1178223419828766}
===========

In conclusion, our study shows that the age of BCVY patients with presence of axillary lymph node involvement after surgery is an independent prognostic predictor of PFS and OS. In addition, axillary lymph node involvement and the presentation of a luminal or HER2^+^ tumor subtype in young women are associated with poor prognosis. Finally, decreased miR-30c expression and axillary lymph node involvement represent a potential prognostic biomarker in BCVY patients. Therefore, more targeted therapies can be specifically invented for and tested in this subgroup.
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